Cell-based Assays Market by Product [Reagents & Assay Kits (Cytotoxicity, GPCR), Cell lines, Plate Readers, HCS, HTS, Software & Assay Development Services], Application (Drug Discovery, ADMET), End-user (Pharmaceutical, CRO) - Global Forecast to 2018

The market for cell-based assays is driven by the preference over biochemical assays and animal models and the emergent 3D cell-based assay techniques in cell-based assays
There has been a substantial rise in the costs to develop a new drug in recent years. This is specially observed when a new compound enters animal testing. The use of animals in experimentation is becoming dearer, due to limitations such as high costs involved in breeding and acquisition of animals, due to the complexity of procedures involved in the in vivo testing, and several other ethical issues and legal issues associated with it. Moreover the traditional biochemical assays also posses many limitations. To counteract these issues there has been a paradigm shift towards the use of cell-based assays.
The consumables formed the largest product segment of the total cell-based assays market in 2013, which includes assay kits and reagents, microplates and cell lines. The largest contribution of consumables was attributed to the large volume market of reagents and assay kits; where most of the innovation is taking place. Drug discovery was the most prominent application of cell-based assays. Within drug discovery, lead identification and optimization accounted for the largest share in 2013. With respect to end users, the pharmaceutical and biotechnology companies commanded the largest share in 2013. These industries are focusing on screening extensive libraries of compounds that could become leads for potential drug candidates. The screening process has helped the pharmaceutical companies to run more cost and time efficient methods.
For accurate results, the low cost label-free technology in cell based assays has emerged as a momentous technology that has been driving the growth of cell-based assay market. With the advancement in the cell stem cell culture, induced pluripotent stem cells will be emerging in near future. With the increasing demand of emergent 3D cell-based assay, it is estimated to be the fastest growing technology in the next five years.
North America accounted for the largest share of the global cell-based assay market in 2013. The presence of a large number of market players along with government funding for drug discovery and increasing number of public-private partnerships are the factors driving the North American cell-based assay market. Countries such as India and China serve as new revenue pockets for the cell-based assay market. Healthcare reforms, government initiatives, growing awareness and increasing investments in drug discovery are encouraging the rising acceptance and adoption of the cell-based assay technology in these regions. The emerging countries in Asia such as China and India will register high growth in the coming years; this can be attributed to the low development costs offered by these nations. Moreover, clinical research organizations are growing at fastest rate and more inclined to set their pace in these nations.
The grey areas while estimating the market size was the overlapping nature of the products and technology while segregating them based on evaluation of endpoints involved. As there is a thin line between products and technology used, both were included while estimating the patient monitoring market.
From an insight perspective, this research report focuses on the qualitative data, market size, share, growth of various segments and sub-segments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats). The report also offers market shares, sizes, and related growth of various segments in the industry. It also focuses on the emerging and high-growth segments of cell-based assay market, high-growth regions, and the initiatives of respective governments.
The competitive landscape covers the growth strategies adopted by industry players in the last three years. The company profiles comprise the basic views on the key players in the cell-based assay market, product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Table Of Contents

1 Introduction (Page No. - 19)
1.1 Objectives of the Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Market Scope
1.6 Research Methodology
1.6.1 Market Size Estimation
1.6.2 Market Crackdown & Data Triangulation
1.6.3 Key Data From Secondary Sources
1.6.4 Key Data Points From Primary Sources
1.6.5 Assumptions

2 Executive Summary (Page No. - 32)

3 Premium Insights (Page No. - 36)
3.1 Global Cell-Based Assays Market
3.2 Market Dynamics
3.3 Snapshot of the Market
3.4 Consumables & Instruments Market For Cell-Based Assays
3.5 Geographic Analysis
3.6 Application Market
3.7 End User Market

4 Market Overview (Page No. - 43)
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Significant Advantages of Cell-Based Assays Over Conventional Techniques Provide Ideal Solution For A Range of Research & Commercial Applications
4.2.1.2 Government Funding and Public-Private Partnerships Support Cell-Based Research Activities
4.2.1.3 Drug Discovery, Major Driver For Cell-Based Assays Market
4.2.1.4 Implementation of Hts and Automation Techniques Accelerates the Drug Discovery Process
4.2.2 Restraints
4.2.2.1 Shortage of Skilled Experts & High Instrument Costs Have A Negative Impact
4.2.2.2 Skepticism About Long-Term Benefits of Reporter Assay Kits May Affect their Adoption
4.2.2.3 Intellectual Property Rights Issues Restrict Innovations in the Market
4.2.3 Opportunities
4.2.3.1 Asian Market Presents High-Growth Opportunities
4.2.3.2 Need to De-Risk Early-Phase Drug Discovery Reinforces Cell-Based toxicity Screening
4.2.3.3 Developments in High-Content Screening and Software to Transform Cell-Based Screening
4.2.4 Trends
4.2.4.1 Use of Stem Cells & 3d Culture Defines the Future of the Market
4.2.4.2 Assay Development and Assay Screening Services Are the Most Prominent Trend
4.2.4.3 Label-Free Technologies Are Set to Transform the Market
4.3 Burning Issues & Challenges
4.3.1 Consistent Supply of Cells Creates A Bottleneck
4.3.2 New Technologies Call For Assay Optimization
4.4 Winning Imperatives
4.4.1 Assay Multiplexing
4.4.2 Assay Miniaturization & Microfluidics
4.5 Porter’s Five Forces Analysis
4.5.1 Threat From New Entrants
4.5.2 Threat From Substitutes
4.5.3 Competitors Rivalry
4.5.4 Bargaining Power of Suppliers
4.5.5 Bargaining Power of Buyers
4.6 Market Share Analysis

5 Cell-Based Assays Market, By Product (Page No. - 63)
5.1 Introduction
5.2 Consumables
5.2.1 Reagents & Assay Kits
5.2.1.1 Cell Growth Assays
5.2.1.2 Cell Death Assays
5.2.1.3 Second Messenger Assays
5.2.1.4 Reporter Gene Assays
5.2.1.5 Other Assays
5.2.2 Microplates
5.2.3 Cell Lines
5.2.3.1 Immortalized Cell Lines
5.2.3.2 Primary Cell Lines
5.2.3.3 Stem Cell Lines
5.2.4 Other Consumables
5.3 Instruments
5.3.1 Detection & Screening Instruments
5.3.1.1 Microplate Readers
5.3.1.2 Flow Cytometers
5.3.1.3 Fluorescent Microscopes
5.3.1.4 High Content Screening Instruments
5.3.1.5 Label-Free Detection Instruments
5.3.1.6 Other Detection and Screening Instruments
5.3.2 Automation & High Throughput Screening Instruments
5.4 Software
5.5 Services

6 Cell-Based Assays Market, By Application (Page No. - 109)
6.1 Introduction
6.2 Basic Research
6.3 Drug Discovery
6.3.1 Target Identification and Validation
6.3.2 Lead Identification & Optimization
6.4 Absorption, Distribution, Metabolism & Excretion (Adme) Studies
6.5 Predictive Toxicology
6.6 Other Applications

7 Cell-Based Assays Market, By End User (Page No. - 126)
7.1 Introduction
7.2 Pharmaceutical & Biotechnology Companies
7.3 Academic & Government Institutions
7.4 Contract Research Organizations (CRO)
7.5 Other End Users (Hospitals/Clinical Labs, Food/ Agriculture Industries & Environmental Labs)

8 Cell-Based Assays, By Geography (Page No. - 136)
8.1 Introduction
8.2 North America
8.2.1 Emphasis on Technological Advancements Drives the U.S. Market
8.2.2 Research Networks in Canada to Boost the Market
8.3 Europe
8.3.1 Decline in Venture Capitalist Investments in Early Drug Discovery Shifts the Burden to Public Funding
8.3.2 Public-Private Partnerships to Accelerate Drug Discovery Process in European Union
8.4 Asia
8.4.1 Stem Cell Research in Japan
8.4.2 Drug Discovery Outsourcing Fuels the Market Growth in China and India
8.5 ROW

9 Competitive Landscape (Page No. - 179)
9.1 Introduction
9.2 New Product Launch
9.3 Agreements, Collaborations & Partnerships
9.4 Acquisitions
9.5 Others

10 Company Profiles (Page No. - 188)
10.1 Becton, Dickinson and Company
10.2 Cell Signaling Technology
10.3 Cisbio Bioassays (Argos Soditic)
10.4 Danaher Corporation
10.5 Discoverx
10.6 EMD Millipore (A Subsidiary of Merck Kgaa)
10.7 Ge Healthcare (Subsidiary of General Electric Company)
10.8 Life Technologies (Thermo Fisher Scientific)
10.9 Perkinelmer, Inc.
10.10 Promega Corporation

*Details on Business Overview, Financials, Product & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.